검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Emicizumab (Emicizumab) Indiana Hemophilia &Thrombosis Cen…·Factor VIII Deficiency, Congenital ORR 14.77% |
|---|---|
Overview Program | Emicizumab |
Overview Company | Indiana Hemophilia &Thrombosis Center, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Factor VIII Deficiency, Congenital |
Overview Indication | Haemophilic Pseudotumour |
Overview Phase | APPROVED |
Overview Status | DISCONTINUED |
MoA Mechanism | Targeted rebalancing agents enhance coagulation by attenuating endogenous anticoagulants such as tissue factor pathway |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | [Evaluation of the efficacy and safety of reduced-dose emicizumab in infants with severe hemophilia A: a single-center real-world study].. To investigate the efficacy and safety of reduced-dose emicizumab (EMI) prophylaxis in infants under one year of age with severe hemophilia A (HA). Medical records of 11 infants aged ≤12 months with severe HA who received reduced-dose EMI in the Departme… |
Clinical Primary efficacy | ORR 14.77% |
Clinical ORR | 14.77% |
Clinical Result source | ClinicalTrials.gov NCT03380780 |
Clinical Data Tier / Score | A · 25 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Emicizumab (Emicizumab) Indiana Hemophilia &Thrombosis Cen…·Factor VIII Deficiency, Congenital ORR 14.77% |
|---|---|
Overview Program | Emicizumab |
Overview Company | Indiana Hemophilia &Thrombosis Center, Inc. |
Overview Modality | ANTIBODY |
Overview Target | Factor VIII Deficiency, Congenital |
Overview Indication | Haemophilic Pseudotumour |
Overview Phase | APPROVED |
Overview Status | DISCONTINUED |
MoA Mechanism | Targeted rebalancing agents enhance coagulation by attenuating endogenous anticoagulants such as tissue factor pathway |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | [Evaluation of the efficacy and safety of reduced-dose emicizumab in infants with severe hemophilia A: a single-center real-world study].. To investigate the efficacy and safety of reduced-dose emicizumab (EMI) prophylaxis in infants under one year of age with severe hemophilia A (HA). Medical records of 11 infants aged ≤12 months with severe HA who received reduced-dose EMI in the Departme… |
Clinical Primary efficacy | ORR 14.77% |
Clinical ORR | 14.77% |
Clinical Result source | ClinicalTrials.gov NCT03380780 |
Clinical Data Tier / Score | A · 25 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교